

Supplementary Table 1. Incidences and subhazard ratios of ischemic stroke or TIA in head and neck cancer patient with and without statin during radiotherapy stratified by demographics and comorbidity in the competing-risk regression model

Ischemic stroke or TIA	Statin						Crude SHR (95% CI)	Adjusted SHR [†] (95% CI)
	No			Yes				
	Event	PY	Rate*	Event	PY	Rate*		
Overall	45	2,708	16.6	64	3,090	20.7	1.45 (1.04–2.00) [†]	1.35 (0.95–1.91)
Age group (yr)								
≤49	4	444	9.00	9	511	17.6	1.12 (0.70–1.80)	1.15 (0.67–1.95)
50–64	23	1,430	16.1	25	1,550	16.1	0.77 (0.62–0.97) [†]	0.83 (0.65–1.05)
≥65	18	834	21.6	30	1,028	29.2	0.69 (0.53–0.91) [§]	0.74 (0.56–0.99) [†]
<i>P</i> for interaction								0.87
Gender								
Women	3	371	8.08	9	453	19.9	4.37 (0.70–27.5)	4.19 (1.03–17.0) [†]
Men	42	2,337	18.0	55	2,636	20.9	1.15 (0.80–1.65)	1.02 (0.69–1.52)
<i>P</i> for interaction								0.24
Comorbidity								
No	0	44	0.00	1	52	19.3	-	-
Yes	45	2,664	16.9	63	3,038	20.7	1.23 (0.86–1.76)	1.09 (0.74–1.61)
<i>P</i> for interaction								<0.001
Medication								
Aspirin								
No	4	413	9.68	3	345	8.69	-	-
Yes	41	2,295	17.9	61	2,744	22.2	1.17 (0.80–1.71)	1.10 (0.74–1.64)
<i>P</i> for interaction								0.28
Clopidogrel								
No	42	2,497	16.8	50	2,370	21.1	1.17 (0.79–1.74)	1.00 (0.63–1.57)
Yes	3	211	14.2	14	719	19.5	2.00 (0.56–7.09)	3.85 (0.36–41.7)
<i>P</i> for interaction								0.26
ACEI								
No	11	1,171	9.39	15	1,090	13.8	2.07 (0.71–6.03)	1.53 (0.46–5.07)
Yes	34	1,537	22.1	49	1,999	24.5	1.13 (0.74–1.74)	1.10 (0.70–1.71)
<i>P</i> for interaction								0.26
ARB								
No	22	1,469	15.0	34	1,276	26.7	2.16 (1.09–4.28) [†]	1.89 (0.92–3.89)
Yes	23	1,239	18.6	30	1,814	16.5	0.93 (0.51–1.70)	0.74 (0.36–1.51)
<i>P</i> for interaction								0.36
Warfarin								
No	44	2,607	16.9	61	2,879	21.2	1.45 (1.00–2.09) [†]	1.31 (0.88–1.94)
Yes	1	101	9.92	3	210	14.3	-	-
<i>P</i> for interaction								0.10
Treatment								
Surgery								
No	37	2,187	16.9	56	2,513	22.3	1.34 (0.90–1.99)	1.32 (0.86–2.01)
Yes	8	521	15.3	8	577	13.9	0.81 (0.23–2.91)	0.85 (0.27–2.61)
<i>P</i> for interaction								0.23
Chemotherapy								
No	9	853	10.6	24	1,031	23.3	2.53 (0.99–6.44)	2.05 (0.74–5.69)

Supplementary Table 1. Continued

Ischemic stroke or TIA	Statin						Crude SHR (95% CI)	Adjusted SHR [†] (95% CI)
	No			Yes				
	Event	PY	Rate*	Event	PY	Rate*		
Yes	36	1,855	19.4	40	2,059	19.4	1.11 (0.69–1.77)	1.03 (0.58–1.84)
<i>P</i> for interaction								0.12
Cetuximab								
No	45	2,689	16.7	64	3,042	21.0	1.27 (0.89–1.81)	1.13 (0.76–1.67)
Yes	0	19	0.00	0	47	0.00	-	-
<i>P</i> for interaction								0.82

TIA, transient ischemic attack; PY, person-year; SHR, subhazard ratio; CI, confidence interval; ACEI, angiotensin-converting-enzyme inhibitor; ARB, angiotensin II receptor blocker.

Incidence rate per 1,000 person-years; [†]Variable found to be significant in the Table 1 were further examined in the multivariable analysis (use of aspirin, clopidogrel, ACEI, and ARB); ^{}*P*<0.05; [§]*P*<0.01.